News

The program is for candidate OCU400, a modifier gene therapy product candidate.

The company hosted a virtual KOL event focusing on applicability and real-world experience with suprachoroidal drug delivery, the SCS as a differentiator in the retinal treatment landscape with a focus on wet AMD, and ongoing SCS clinical programs.

Kay Durairaj, MD, FACS, a facial plastic surgeon points out that the use of hyaluronidase in the periorbital region demands a meticulous approach due to the delicate anatomy and high risk of complications.

According to the company, the wearable smart glasses with both vision enhancement and assistance will be introduced at the American Retina Forum National Meeting

The Summit will feature 18+ course hours and an extensive resource library to support practice adoption of AT IOLs

According to the company, additional data from its Phase 2 ARCHER trial showed both vision protection in standard and low light conditions, and structural protection in regions of the eye key for visual acuity.

The service expands ophthalmological capabilities and enables providers to deliver the gift of sight to patients with complex retinal conditions in Harlem.

Results suggest higher exposures to lower temperatures and certain air pollutants could result in worsened ocular symptoms and increased tear osmolarity.

A team of 14 eyecare professionals made the recent trip including faculty from the Loyola Medicine Department of Ophthalmology and faculty and residents from Cook County Health, Northwestern Medicine, Wills Eye Hospital in Philadelphia, the University of Toledo College of Medicine and Champlain Ophthalmology in Bethesda, Maryland.

The US gymnast has become an overnight sensation for competing with strabismus and coloboma at the 2024 Olympic Games in Paris.

Statin use was linked with increased glaucoma likelihood in the overall adult All of Us Research Program population with hyperlipidemia, in individuals with optimal or high LDL-C levels, and in individuals from 60 to 69 years old.

This Week in Ophthalmology is a video series highlighting some of the top articles featured on the Ophthalmology Times website.

The company is developing ixoberogene soroparvovec, its clinical-stage gene therapy product candidate, for the treatment of wet AMD.

According to the researchers, the findings suggest drusen formation is a downstream effect of AKT2-related lysosome dysfunction and points to a new target for therapeutic intervention.

As a medical student at the University of Miami Miller School of Medicine, Ashlyn Anzu Gary landed the unique opportunity to help launch an interdisciplinary clinical research program exploring hypnotherapy as a treatment for people with chronic eye pain.

In a study, a team of researchers with the OhioHealth Grant Medical Center Family Medicine practice implemented diabetic retinopathy screening using in-clinic retinal photographs and automated software analysis to increase screening rates.

According to the organization, professionals from almost every country and territory across the globe—including nearly 15% of the world's ophthalmologists—have trained on the platform.

According to the company, VCN-01, its lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. The FDA had previously granted orphan drug designation to VCN-01 for treatment of retinoblastoma.

Cochair Kelly K. Nichols, OD, PhD, MPH, FAAO, highlights her passion for dry eye research and the vital collaboration between ophthalmology and optometry at EyeCon.

The microRNA(miR)-17-92 cluster is known to play an important role in cell signaling, but its specific functions in the eye are not well understood. The researchers’ focus lies in gaining insights into the mechanisms of miR-17-92 cluster members and their effects on IOP.

KIO-30 is a small molecule photoswitch that selectively confers light-sensing capabilities to retinal ganglion cells following the degeneration of photoreceptors in inherited retinal diseases.

Prevent Blindness provides opportunities for awareness and action in support of new legislation to provide much-needed funding for children’s vision programs in the United States.

Nebraska Medicine taps technology for use in clinics.

The results from the trial in China met both the primary and secondary endpoints with no serious adverse events or new safety signals.

The companies announced that they will be working to develop SGN’s micellar nanoparticle platform to be used with Eyenovia’s Optejet dispenser.

The positive opinion from the CHMP comes with the recommendation that Vevizye be granted marketing authorization for the treatment of dry eye disease in the European Union.

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

The study helped identify predisposing factors for severe SANS in astronauts.

According to the company, its ViaLase Laser combines state-of-the-art femtosecond laser technology with micron-level image guidance to deliver the first femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT), marking a shift in glaucoma care.